Nutriband Inc. (NTRB)

Nutriband Inc. (NTRB) Healthcare & Pipeline Overview

Nutriband Inc. is a biotechnology company specializing in transdermal drug delivery systems, focusing on developing abuse-deterrent formulations like AVERSA fentanyl for chronic pain management. The company aims to provide safer opioid therapies and expand its portfolio of transdermal products addressing various medical needs.

What Is the Investment Thesis for NTRB?

Nutriband Inc. presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The company's focus on abuse-deterrent transdermal drug delivery systems, particularly AVERSA fentanyl, addresses a significant market need given the ongoing opioid crisis. Successful development and commercialization of AVERSA fentanyl could drive substantial revenue growth. Key value drivers include regulatory approvals, strategic partnerships, and expansion of the product pipeline. The company's small market capitalization ($0.05B) offers significant upside potential, but also exposes investors to substantial risk. A profit margin of -404.1% indicates that the company is not yet profitable and relies on external funding. Upcoming milestones include clinical trial results and potential FDA submissions for AVERSA fentanyl. The company's beta of 1.93 suggests high volatility, reflecting the speculative nature of biotechnology investments.

Based on FMP financials and quantitative analysis

NTRB Key Highlights

• Market capitalization of $38.29M indicates a small-cap company with high growth potential but also higher risk.
• Gross margin of 24.9% shows the potential for profitability as the company scales up production and sales.
• Profit margin of -404.1% highlights the company's current lack of profitability and reliance on external funding.
• Beta of 1.93 suggests a high level of volatility compared to the market, reflecting the speculative nature of the biotechnology industry.
• Focus on abuse-deterrent transdermal technology addresses a critical need in the opioid crisis, potentially leading to significant market demand.

Who Are NTRB's Competitors?

NTRB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NTRB's Key Strengths?

• Innovative transdermal drug delivery technology.
• Focus on abuse-deterrent formulations.
• Potential to address the opioid crisis.
• License agreement for RAMBAM Closed System Transfer Devices.

What Are NTRB's Weaknesses?

• Limited financial resources.
• Small market capitalization.
• Dependence on regulatory approvals.
• Negative profit margin.

What Could Drive NTRB Stock Higher?

• Clinical trial results for AVERSA fentanyl, expected in Q4 2026, will provide critical data on its efficacy and safety.
• Potential FDA submission for AVERSA fentanyl, anticipated in early 2027, could lead to regulatory approval and commercialization.
• Expansion of the transdermal product pipeline, with new products targeting different therapeutic areas.
• Strategic partnerships and licensing agreements to accelerate product development and market access.

What Are the Key Risks for NTRB?

• Regulatory hurdles and delays in obtaining FDA approval for AVERSA fentanyl.
• Competition from established pharmaceutical companies with greater resources.
• Product liability risks associated with transdermal drug delivery systems.
• Dependence on external funding to support research and development activities.
• Negative profit margin and the need to achieve profitability.

What Are the Growth Opportunities for NTRB?

• AVERSA Fentanyl Commercialization: The successful commercialization of AVERSA fentanyl represents a significant growth opportunity for Nutriband Inc. The market for chronic pain management is substantial, and the abuse-deterrent properties of AVERSA fentanyl could capture a significant share. The global pain management market is projected to reach $91.5 billion by 2028. The timeline for this growth opportunity depends on regulatory approvals and successful market penetration, with potential revenue generation starting within the next 2-3 years.
• Expansion of Transdermal Product Pipeline: Nutriband Inc.'s development of other transdermal products, such as AVERSA buprenorphine and AVERSA methylphenidate, offers additional growth potential. These products target different therapeutic areas and expand the company's market reach. Each product addresses specific medical needs and contributes to a diversified revenue stream. The timeline for this growth opportunity is dependent on clinical trial progress and regulatory approvals, with potential product launches over the next 3-5 years.
• Partnerships and Licensing Agreements: Strategic partnerships and licensing agreements can accelerate Nutriband Inc.'s growth by leveraging external expertise and resources. The company's existing agreement with Rambam Med-Tech Ltd. demonstrates the potential for collaborative innovation. Forming additional partnerships with pharmaceutical companies or research institutions could provide access to new technologies and markets. The impact of this growth opportunity is contingent on the terms and success of future partnerships, with potential benefits realized within the next 1-2 years.
• Geographic Expansion: Expanding into new geographic markets represents another growth opportunity for Nutriband Inc. The company's products could be marketed in regions with high demand for pain management solutions and a growing awareness of the opioid crisis. International expansion requires navigating different regulatory landscapes and establishing distribution networks. The timeline for this growth opportunity is dependent on market research and regulatory approvals in target countries, with potential market entry over the next 3-5 years.
• RAMBAM Closed System Transfer Devices: The development and commercialization of the RAMBAM Closed System Transfer Devices, through the license agreement with Rambam Med-Tech Ltd., presents a growth opportunity by enhancing drug administration safety and efficiency. These devices can be integrated with Nutriband's transdermal products, offering a comprehensive solution. The market for closed system transfer devices is growing, driven by the need to reduce healthcare worker exposure to hazardous drugs. The timeline for this growth opportunity depends on regulatory approvals and market adoption, with potential revenue generation starting within the next 2-3 years.

What Opportunities Does NTRB Have?

• Commercialization of AVERSA fentanyl.
• Expansion of transdermal product pipeline.
• Strategic partnerships and licensing agreements.
• Geographic expansion.

What Threats Does NTRB Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Product liability risks.
• Changes in healthcare policies.

What Are NTRB's Competitive Advantages?

• Proprietary transdermal drug delivery technology.
• Abuse-deterrent formulations that address a critical need.
• Patent protection for its AVERSA technology.
• Strategic partnerships and licensing agreements.

What Does NTRB Do?

Nutriband Inc., incorporated in 2016 and headquartered in Orlando, Florida, is a biotechnology company dedicated to developing and commercializing a portfolio of transdermal pharmaceutical products. The company's primary focus is on creating innovative drug delivery systems that offer improved safety and efficacy compared to traditional methods. Their lead product, AVERSA fentanyl, is an abuse-deterrent fentanyl transdermal system designed to provide extended-release pain relief for patients requiring around-the-clock opioid therapy. This system incorporates features aimed at reducing the potential for misuse and abuse, addressing a critical need in the management of chronic pain. In addition to AVERSA fentanyl, Nutriband Inc. is also developing other transdermal products, including AVERSA buprenorphine and AVERSA methylphenidate, targeting different therapeutic areas. The company is also exploring transdermal delivery systems for exenatide, a drug used in the treatment of type 2 diabetes, and follicle stimulating hormone (FSH) for infertility. These efforts reflect Nutriband's commitment to expanding its product pipeline and addressing a wide range of medical conditions through innovative transdermal technologies. Nutriband Inc. also has a license agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices, which are designed to enhance the safety and efficiency of drug administration. This collaboration highlights the company's focus on strategic partnerships and leveraging external expertise to advance its product development efforts. Nutriband's business model centers around the development, manufacturing, and commercialization of its proprietary transdermal products, with a focus on addressing unmet medical needs and improving patient outcomes.

What Products and Services Does NTRB Offer?

• Develops transdermal pharmaceutical products.
• Focuses on abuse-deterrent technologies for opioid therapies.
• Creates extended-release transdermal systems for chronic pain management.
• Develops AVERSA fentanyl as an abuse-deterrent fentanyl transdermal system.
• Explores transdermal delivery systems for various drugs, including buprenorphine and methylphenidate.
• Has a license agreement for RAMBAM Closed System Transfer Devices.

How Does NTRB Make Money?

• Develops proprietary transdermal drug delivery systems.
• Seeks regulatory approvals for its products.
• Commercializes its products through partnerships and direct sales.
• Generates revenue through product sales and licensing agreements.

What Industry Does NTRB Operate In?

Nutriband Inc. operates within the biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. The market for transdermal drug delivery systems is growing, driven by the demand for non-invasive and convenient drug administration methods. The opioid crisis has created a pressing need for abuse-deterrent formulations, positioning Nutriband's AVERSA fentanyl as a potential solution. The competitive landscape includes established pharmaceutical companies and smaller biotech firms developing similar technologies. Success in this industry requires strong intellectual property, regulatory expertise, and effective commercialization strategies. The global biotechnology market is projected to reach $3.44 trillion by 2030, growing at a CAGR of 12.3% from 2022.

Who Are NTRB's Key Customers?

• Patients requiring chronic pain management.
• Clinicians prescribing opioid therapies.
• Pharmacies dispensing transdermal medications.
• Hospitals and healthcare facilities.

FY2027 estForward Outlook

Wall Street analysts project Nutriband Inc. revenue of about $95.4M for fiscal 2027, with EPS near $1.57.

F-Score 4/9Financial Health

Nutriband Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 12.02 places it in the safe zone, indicating low near-term bankruptcy risk.

Key Financial Metrics

Its free cash flow yield is -11.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.0%, the inverse of the P/E and a quick read on earnings relative to price.

Nutriband Inc. (NTRB) Valuation Context

Valued at $38.29M, NTRB is classified as a micro-cap stock. Relative to its peer group, NTRB's quantitative score of 27/100 is below the peer average of 74/100.

Company Profile

Nutriband Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Gareth Sheridan. NTRB has traded publicly since 2021.

NTRB Financials

NTRB Latest News

NTRB Analyst Consensus

NTRB MoonshotScore

NTRB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources